Developer docs
API playgroundTry for free, no card

Search company profiles

Bioretec

Full company profile

uuid00005sj

Namestring
Bioretec
Legal namestring
Bioretec Ltd
Websiteurl
bioretec.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Bioretec Ltd is a Finland-headquartered, publicly listed (Nasdaq First North Growth Market Finland) medical device company that designs, manufactures, and commercializes bioabsorbable orthopedic implants for fracture fixation and bone repair, with a primary focus on pediatric and adult orthopedic surgery and current commercial emphasis on foot and ankle procedures. Founded in 2003 in Tampere by Professor Pertti Törmälä and operating with approximately 60 employees, Bioretec runs two proprietary product platforms: the RemeOs line based on a magnesium-calcium-zinc absorbable metal alloy (notably free of rare earth elements), and the Activa line based on self-reinforced PLGA 85/15 biopolymer with patented Auto-Compression and Self-Locking SL functionality. The company's clinical positioning rests on implants that degrade in approximately two years, eliminating the need for secondary removal surgery — a particularly relevant benefit in pediatric patients whose ongoing bone growth otherwise typically requires metal implant extraction.

The company has built a defensible regulatory footprint: FDA De Novo market authorization for RemeOs Screw LAG Solid in March 2023 (first absorbable metal orthopedic implant in the U.S.), CE Mark under EU MDR for RemeOs Trauma Screw in January 2025, three FDA Breakthrough Device Designations (RemeOs portfolio), and CMS Transitional Pass-Through Payment status with HCPCS code C1741 effective October 1, 2025. The product portfolio spans RemeOs screws (LAG, LAG Solid, COM, FT), RemeOs DrillPin and a Spinal Interbody Cage in development, and Activa products including interference screws, cannulated screws, nails, pins, and IM-Nails, collectively used in over 400,000 procedures historically with zero reported adverse events.

Bioretec operates a hybrid go-to-market: a direct U.S. sales force led by VP of Sales USA Frank Sarcone targeting hospitals and surgery centers, combined with an OUS organization under VP Jordy Winters and an extensive distributor network covering approximately 40 countries across Europe, Asia, Africa, Latin America, and the Middle East. Revenue is generated from one-time hardware sales of implants per surgical procedure, with FY2025 net sales of EUR 3.522 million (down 22.5% YoY) and a reset financial target of exceeding EUR 10 million in net sales by 2028. The company has undergone multiple capital raises — including EUR 9.2 million via rights issue in June 2025 and EUR 12.9 million in April 2026 — and a CEO transition (Sarah van Hellenberg Hubar-Fisher succeeding Alan Donze in 2025) amid production-side restructuring.

Short descriptiontext

Bioretec Ltd is a Finnish publicly listed medical device company that designs and commercializes bioabsorbable orthopedic implants (RemeOs magnesium alloy and Activa PLGA polymer platforms) for fracture fixation in pediatric and adult orthopedic surgery, distributed via direct sales in the U.S. and approximately 40-country distributor network globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTampere, Finland
HQ citystring
Tampere
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioabsorbable orthopedic implants, magnesium alloy implants, polymer bone fixation, absorbable fracture fixation, orthopedic medical devices
Industry1 code
PRIMARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Implants / Bioabsorbable Medical Devices
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Orthopedic Implant Sales
TypeHardware Sales
Description

Bioretec generates revenue primarily from the sale of bioabsorbable orthopedic implants including RemeOs (magnesium alloy screws) and Activa (PLGA polymer implants). Products are sold through direct sales force and distributor network in approximately 40 countries. Revenue model is traditional medical device hardware sales - one-time purchase per procedure.

bioretec.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1RemeOs
Description

Premium absorbable orthopedic implant line using state-of-the-art absorbable metal alloy technology. Products are designed to promote natural bone healing without requiring removal surgery. Includes Screw LAG, Screw COM, Screw FT, and Screw LAG Solid variants.

bioretec.com
+1 more record
Core offering1 text field

Bioretec designs, develops, and manufactures bioabsorbable orthopedic implants for fracture fixation and bone repair. Its two product lines—RemeOs (proprietary magnesium-calcium-zinc alloy) and Activa (self-reinforced PLGA 85/15 biopolymer)—are sold to hospitals, ambulatory surgery centers, and orthopedic surgeons for both pediatric and adult procedures, with implants engineered to degrade naturally in the body in approximately two years and eliminate the need for removal surgery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% of patients achieved fracture consolidation by 6 weeks with complete healing observed by 12 weeks
+4 more records
Product overview1 text field

Bioretec offers two distinct absorbable orthopedic implant product lines: RemeOs™ (based on bioactive magnesium alloy technology) and Activa™ (based on self-reinforced PLGA biopolymer). RemeOs™ products include multiple screw configurations (LAG, LAG Solid, COM, FT), the DrillPin, and the Spinal Cage (in development), all utilizing proprietary absorbable metal alloy that provides mechanical strength while supporting natural bone healing. Activa™ products comprise interference screws, cannulated screws, nails, pins, and surgical screws using PLGA 85/15 polymer with patented self-reinforcement technology. Both product lines eliminate the need for removal surgeries as implants degrade naturally and are replaced by bone. Products are CE marked and/or FDA cleared/authorized, marketed in approximately 40 countries worldwide.

Product and service13 records
1RemeOs™ Screw LAG
CategoryRemeOs absorbable metal alloy implants
Description

Partially threaded and cannulated screw using high-performance magnesium alloy and hybrid composite technology. Provides strong and stable fixation during healing and gradually degrades as it is replaced by bone; intended for orthopedic surgeons and hospitals performing fracture fixation.

2RemeOs™ Screw LAG Solid
CategoryRemeOs absorbable metal alloy implants
Description

Partially threaded and non-cannulated screw made from proprietary magnesium alloy; first-and-only osteopromotive absorbable metal implant for orthopedic use in the United States. Sold to hospitals, ambulatory surgery centers, and orthopedic surgeons for fracture fixation procedures.

3RemeOs™ Screw COM
CategoryRemeOs absorbable metal alloy implants
Description

Headless, partially threaded compression screw designed for specific orthopedic fixation applications using absorbable metal alloy technology; targeted at orthopedic surgeons performing foot and ankle, trauma, and reconstructive procedures.

4RemeOs™ Screw FT
CategoryRemeOs absorbable metal alloy implants
Description

Headless, fully-threaded compression screw with enhanced fixation properties using magnesium alloy and hybrid composite materials; intended for orthopedic fracture fixation procedures where additional thread engagement is required.

5RemeOs™ DrillPin
CategoryRemeOs absorbable metal alloy implants
Description

Biodegradable magnesium alloy implant for fracture fixation in pediatric and adult patients, designed for use in hospitals and surgery centers performing orthopedic procedures.

6RemeOs™ Spinal Cage
CategoryRemeOs absorbable metal alloy implants (development pipeline)
Description

Next-generation interbody cage using hybrid composite material engineered to regulate degradation speed; in proof-of-concept phase targeting spinal interbody fusion procedures for spine surgeons and hospitals.

7ActivaScrew™ Interference
CategoryActiva absorbable PLGA biopolymer implants
Description

Advanced absorbable interference screw implant made from proprietary self-reinforced PLGA polymer; used in fracture treatment with natural degradation within approximately two years, sold to orthopedic surgeons and hospitals.

8ActivaScrew™ Interference TCP
CategoryActiva absorbable PLGA biopolymer implants
Description

Advanced absorbable biocomposite interference screw with enhanced material properties for secure fixation in orthopedic procedures; targeted at sports medicine and ligament reconstruction surgeries.

9ActivaScrew™ Cannulated
CategoryActiva absorbable PLGA biopolymer implants
Description

Advanced absorbable cannulated screw implant used in various orthopedic surgical procedures for bone fixation; intended for hospitals and surgeons requiring guide-wire-assisted placement.

10ActivaNail™
CategoryActiva absorbable PLGA biopolymer implants
Description

Advanced absorbable nail implant used in fixation procedures, providing secure stabilization during bone healing with natural degradation; intended for orthopedic surgeons and hospitals performing fracture fixation and osteotomy procedures.

11Activa IM-Nail™
CategoryActiva absorbable PLGA biopolymer implants
Description

World's first fully absorbable elastic intramedullary nail for orthopedic fixation, enabling less invasive surgical techniques with natural material absorption; intended for pediatric and adult fracture treatment.

12ActivaPin™
CategoryActiva absorbable PLGA biopolymer implants
Description

Advanced absorbable pin implant used for fixation of bone fractures and soft tissue injuries when appropriate immobilization is applied; targeted at orthopedic and trauma surgeons.

13Activa Screw™
CategoryActiva absorbable PLGA biopolymer implants
Description

Absorbable surgical screw for fracture treatment, made from self-reinforced PLGA polymer with over 20 years of clinical use and hundreds of thousands of successful applications; sold to hospitals and orthopedic surgeons worldwide.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-19
Description

Medical mission partnership in Kiabe, Kenya where Bioretec donated Activa implants for 50 pediatric orthopedic surgeries. Partnership included training local surgeons on less invasive techniques. Demonstrates product benefits in developing world context where removal surgeries are impractical.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Approximately 40 distributors globally including: Alpha Trading (Bangladesh), ABL Alpstein (Peru), LH SAS (Colombia), Columbus Medical (Netherlands), Medeco-ch (Switzerland), Acuna y Fombona (Spain), Novastep (France), Kir-Fix Oy (Finland), Fischer Medical (Denmark), and others. Distributors cover Europe, Asia, Africa, Latin America, and Middle East.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the world's largest orthopedic medical device companies with a broad portfolio of trauma, foot & ankle, and sports medicine implants. Stryker is a primary incumbent Bioretec must displace in the hospital and ASC channels, but does not focus on bioabsorbable technology.

TypeBroad incumbent
Description

Global orthopedic leader within J&J MedTech, with the deepest trauma and extremities fixation portfolio and surgeon relationships. Represents the dominant metal-implant incumbent that Bioretec's absorbable screws must displace in shared hospital accounts.

TypeBroad incumbent
Description

Global medical device company with strong trauma, extremities, and sports medicine franchises. Bioretec's incoming Head of R&D Conan Cavanagh previously served as Engineering Director at Smith & Nephew, evidencing direct competitive overlap and the talent pool that flows between the two.

TypeBroad incumbent
Description

Major orthopedic and trauma implant manufacturer with a global direct sales force and broad hospital contracts. Provides the standard-of-care metal screw, plate, and nail alternatives that Bioretec's absorbable RemeOs and Activa lines compete against procedurally.

TypeDirect peer
Description

Privately held leader in sports medicine and orthopedic soft-tissue-to-bone fixation, with strong surgeon relationships in foot & ankle. Arthrex competes most directly with Bioretec's RemeOs interference screws and ActivaScrew Interference product family in the ASC and sports medicine channels.

TypeDirect peer
Description

Specialty surgical and orthopedic implant company with a meaningful extremities and sports medicine portfolio. Operates in many of the same hospital and ASC accounts as Bioretec and offers overlapping screw and fixation product categories for foot & ankle and hand surgeons.

TypeDirect peer
Description

Focused orthopedic trauma and biologics company with bone growth stimulation and fracture fixation products. Closely comparable to Bioretec in scale, strategic focus, and reliance on novel regenerative/orthobiologic mechanisms of action in fracture healing.

TypeDirect peer
Description

Mid-cap medical device company with a substantial orthopedic and sports medicine portfolio including interference screws and fixation devices. Competes with Bioretec's ActivaScrew Interference line in arthroscopy and sports medicine channels.

TypeEmerging player
Description

Smaller U.S. orthopedic device company focused on shape-memory nickel-titanium (NiTiNOL) and other novel implant materials for foot & ankle and trauma. Comparable to Bioretec in scale and in pursuing material-science-driven differentiation in a market dominated by stainless steel and titanium screws.

TypeEmerging player
Description

Early-stage orthopedic biomaterials company developing bioresorbable and bio-integrative implant technologies. Highly comparable to Bioretec in its focus on enabling bone healing without permanent hardware, though still in pre-commercial development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioretec

Orthopedic Implants / Bioabsorbable Medical Devicesbioretec.com

Bioretec Ltd is a Finnish publicly listed medical device company that designs and commercializes bioabsorbable orthopedic implants (RemeOs magnesium alloy and Activa PLGA polymer platforms) for fracture fixation in pediatric and adult orthopedic surgery, distributed via direct sales in the U.S. and approximately 40-country distributor network globally.

What Bioretec does

Bioretec Ltd is a Finland-headquartered, publicly listed (Nasdaq First North Growth Market Finland) medical device company that designs, manufactures, and commercializes bioabsorbable orthopedic implants for fracture fixation and bone repair, with a primary focus on pediatric and adult orthopedic surgery and current commercial emphasis on foot and ankle procedures. Founded in 2003 in Tampere by Professor Pertti Törmälä and operating with approximately 60 employees, Bioretec runs two proprietary product platforms: the RemeOs line based on a magnesium-calcium-zinc absorbable metal alloy (notably free of rare earth elements), and the Activa line based on self-reinforced PLGA 85/15 biopolymer with patented Auto-Compression and Self-Locking SL functionality. The company's clinical positioning rests on implants that degrade in approximately two years, eliminating the need for secondary removal surgery — a particularly relevant benefit in pediatric patients whose ongoing bone growth otherwise typically requires metal implant extraction.

The company has built a defensible regulatory footprint: FDA De Novo market authorization for RemeOs Screw LAG Solid in March 2023 (first absorbable metal orthopedic implant in the U.S.), CE Mark under EU MDR for RemeOs Trauma Screw in January 2025, three FDA Breakthrough Device Designations (RemeOs portfolio), and CMS Transitional Pass-Through Payment status with HCPCS code C1741 effective October 1, 2025. The product portfolio spans RemeOs screws (LAG, LAG Solid, COM, FT), RemeOs DrillPin and a Spinal Interbody Cage in development, and Activa products including interference screws, cannulated screws, nails, pins, and IM-Nails, collectively used in over 400,000 procedures historically with zero reported adverse events.

Bioretec operates a hybrid go-to-market: a direct U.S. sales force led by VP of Sales USA Frank Sarcone targeting hospitals and surgery centers, combined with an OUS organization under VP Jordy Winters and an extensive distributor network covering approximately 40 countries across Europe, Asia, Africa, Latin America, and the Middle East. Revenue is generated from one-time hardware sales of implants per surgical procedure, with FY2025 net sales of EUR 3.522 million (down 22.5% YoY) and a reset financial target of exceeding EUR 10 million in net sales by 2028. The company has undergone multiple capital raises — including EUR 9.2 million via rights issue in June 2025 and EUR 12.9 million in April 2026 — and a CEO transition (Sarah van Hellenberg Hubar-Fisher succeeding Alan Donze in 2025) amid production-side restructuring.

Bioretec firmographics

Firmographics
Name
Bioretec
Legal name
Bioretec Ltd
Website
https://bioretec.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Bioretec Ltd is a Finnish publicly listed medical device company that designs and commercializes bioabsorbable orthopedic implants (RemeOs magnesium alloy and Activa PLGA polymer platforms) for fracture fixation in pediatric and adult orthopedic surgery, distributed via direct sales in the U.S. and approximately 40-country distributor network globally.
Ownership category
akta.pro rank

Bioretec industry classification

Industry
Product category
Orthopedic Implants / Bioabsorbable Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Bioabsorbable orthopedic implants
  • Magnesium alloy implants
  • Polymer bone fixation
  • Absorbable fracture fixation
  • Orthopedic medical devices

Where Bioretec is headquartered

Location

Headquarters

HQ city
Tampere
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Bioretec business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Orthopedic Implant Sales: Bioretec generates revenue primarily from the sale of bioabsorbable orthopedic implants including RemeOs (magnesium alloy screws) and Activa (PLGA polymer implants). Products are sold through direct sales force and distributor network in approximately 40 countries. Revenue model is traditional medical device hardware sales - one-time purchase per procedure.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Bioretec product offering

Product offering

Core offering

Bioretec designs, develops, and manufactures bioabsorbable orthopedic implants for fracture fixation and bone repair. Its two product lines—RemeOs (proprietary magnesium-calcium-zinc alloy) and Activa (self-reinforced PLGA 85/15 biopolymer)—are sold to hospitals, ambulatory surgery centers, and orthopedic surgeons for both pediatric and adult procedures, with implants engineered to degrade naturally in the body in approximately two years and eliminate the need for removal surgery.

Product overview

Bioretec offers two distinct absorbable orthopedic implant product lines: RemeOs™ (based on bioactive magnesium alloy technology) and Activa™ (based on self-reinforced PLGA biopolymer). RemeOs™ products include multiple screw configurations (LAG, LAG Solid, COM, FT), the DrillPin, and the Spinal Cage (in development), all utilizing proprietary absorbable metal alloy that provides mechanical strength while supporting natural bone healing. Activa™ products comprise interference screws, cannulated screws, nails, pins, and surgical screws using PLGA 85/15 polymer with patented self-reinforcement technology. Both product lines eliminate the need for removal surgeries as implants degrade naturally and are replaced by bone. Products are CE marked and/or FDA cleared/authorized, marketed in approximately 40 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • RemeOs: Premium absorbable orthopedic implant line using state-of-the-art absorbable metal alloy technology. Products are designed to promote natural bone healing without requiring removal surgery. Includes Screw LAG, Screw COM, Screw FT, and Screw LAG Solid variants.
  • Activa

Products and services

  • RemeOs™ Screw LAG Partially threaded and cannulated screw using high-performance magnesium alloy and hybrid composite technology. Provides strong and stable fixation during healing and gradually degrades as it is replaced by bone; intended for orthopedic surgeons and hospitals performing fracture fixation.
  • RemeOs™ Screw LAG Solid Partially threaded and non-cannulated screw made from proprietary magnesium alloy; first-and-only osteopromotive absorbable metal implant for orthopedic use in the United States. Sold to hospitals, ambulatory surgery centers, and orthopedic surgeons for fracture fixation procedures.
  • RemeOs™ Screw COM Headless, partially threaded compression screw designed for specific orthopedic fixation applications using absorbable metal alloy technology; targeted at orthopedic surgeons performing foot and ankle, trauma, and reconstructive procedures.
  • RemeOs™ Screw FT Headless, fully-threaded compression screw with enhanced fixation properties using magnesium alloy and hybrid composite materials; intended for orthopedic fracture fixation procedures where additional thread engagement is required.
  • RemeOs™ DrillPin Biodegradable magnesium alloy implant for fracture fixation in pediatric and adult patients, designed for use in hospitals and surgery centers performing orthopedic procedures.
  • RemeOs™ Spinal Cage Next-generation interbody cage using hybrid composite material engineered to regulate degradation speed; in proof-of-concept phase targeting spinal interbody fusion procedures for spine surgeons and hospitals.
  • ActivaScrew™ Interference Advanced absorbable interference screw implant made from proprietary self-reinforced PLGA polymer; used in fracture treatment with natural degradation within approximately two years, sold to orthopedic surgeons and hospitals.
  • ActivaScrew™ Interference TCP Advanced absorbable biocomposite interference screw with enhanced material properties for secure fixation in orthopedic procedures; targeted at sports medicine and ligament reconstruction surgeries.
  • ActivaScrew™ Cannulated Advanced absorbable cannulated screw implant used in various orthopedic surgical procedures for bone fixation; intended for hospitals and surgeons requiring guide-wire-assisted placement.
  • ActivaNail™ Advanced absorbable nail implant used in fixation procedures, providing secure stabilization during bone healing with natural degradation; intended for orthopedic surgeons and hospitals performing fracture fixation and osteotomy procedures.
  • Activa IM-Nail™ World's first fully absorbable elastic intramedullary nail for orthopedic fixation, enabling less invasive surgical techniques with natural material absorption; intended for pediatric and adult fracture treatment.
  • ActivaPin™ Advanced absorbable pin implant used for fixation of bone fractures and soft tissue injuries when appropriate immobilization is applied; targeted at orthopedic and trauma surgeons.
  • Activa Screw™ Absorbable surgical screw for fracture treatment, made from self-reinforced PLGA polymer with over 20 years of clinical use and hundreds of thousands of successful applications; sold to hospitals and orthopedic surgeons worldwide.

Quantifiable outcome

  • 90% of patients achieved fracture consolidation by 6 weeks with complete healing observed by 12 weeks
  • +4 more outcomes

Companies that use Bioretec

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Bioretec technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Bioretec partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Cure International Clinic (Kenya)minorStrategic or Co-development Partner · 19 June 2025Medical mission partnership in Kiabe, Kenya where Bioretec donated Activa implants for 50 pediatric orthopedic surgeries. Partnership included training local surgeons on less invasive techniques. Demonstrates product benefits in developing world context where removal surgeries are impractical.
  • Global Distributor NetworkcoreChannel Partner/ Reseller/ DistributorApproximately 40 distributors globally including: Alpha Trading (Bangladesh), ABL Alpstein (Peru), LH SAS (Colombia), Columbus Medical (Netherlands), Medeco-ch (Switzerland), Acuna y Fombona (Spain), Novastep (France), Kir-Fix Oy (Finland), Fischer Medical (Denmark), and others. Distributors cover Europe, Asia, Africa, Latin America, and Middle East.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Bioretec competitors and assessment

Company assessment

Broad incumbents

  • Stryker: One of the world's largest orthopedic medical device companies with a broad portfolio of trauma, foot & ankle, and sports medicine implants. Stryker is a primary incumbent Bioretec must displace in the hospital and ASC channels, but does not focus on bioabsorbable technology.
  • Johnson & Johnson (DePuy Synthes): Global orthopedic leader within J&J MedTech, with the deepest trauma and extremities fixation portfolio and surgeon relationships. Represents the dominant metal-implant incumbent that Bioretec's absorbable screws must displace in shared hospital accounts.
  • Smith & Nephew: Global medical device company with strong trauma, extremities, and sports medicine franchises. Bioretec's incoming Head of R&D Conan Cavanagh previously served as Engineering Director at Smith & Nephew, evidencing direct competitive overlap and the talent pool that flows between the two.
  • Zimmer Biomet: Major orthopedic and trauma implant manufacturer with a global direct sales force and broad hospital contracts. Provides the standard-of-care metal screw, plate, and nail alternatives that Bioretec's absorbable RemeOs and Activa lines compete against procedurally.

Direct peers

  • Arthrex: Privately held leader in sports medicine and orthopedic soft-tissue-to-bone fixation, with strong surgeon relationships in foot & ankle. Arthrex competes most directly with Bioretec's RemeOs interference screws and ActivaScrew Interference product family in the ASC and sports medicine channels.
  • Integra LifeSciences: Specialty surgical and orthopedic implant company with a meaningful extremities and sports medicine portfolio. Operates in many of the same hospital and ASC accounts as Bioretec and offers overlapping screw and fixation product categories for foot & ankle and hand surgeons.
  • Orthofix Medical: Focused orthopedic trauma and biologics company with bone growth stimulation and fracture fixation products. Closely comparable to Bioretec in scale, strategic focus, and reliance on novel regenerative/orthobiologic mechanisms of action in fracture healing.
  • CONMED: Mid-cap medical device company with a substantial orthopedic and sports medicine portfolio including interference screws and fixation devices. Competes with Bioretec's ActivaScrew Interference line in arthroscopy and sports medicine channels.

Emerging players

  • MedShape: Smaller U.S. orthopedic device company focused on shape-memory nickel-titanium (NiTiNOL) and other novel implant materials for foot & ankle and trauma. Comparable to Bioretec in scale and in pursuing material-science-driven differentiation in a market dominated by stainless steel and titanium screws.
  • Acuitive Technologies: Early-stage orthopedic biomaterials company developing bioresorbable and bio-integrative implant technologies. Highly comparable to Bioretec in its focus on enabling bone healing without permanent hardware, though still in pre-commercial development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Bioretec compliance and trust

Trust signal

Compliance10 records

Bioretec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioretec leadership team

Management profile

Number of profiles

Profiles10 records

Bioretec funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioretec M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioretec

What does Bioretec do?

Bioretec designs, develops, and manufactures bioabsorbable orthopedic implants for fracture fixation and bone repair. Its two product lines—RemeOs (proprietary magnesium-calcium-zinc alloy) and Activa (self-reinforced PLGA 85/15 biopolymer)—are sold to hospitals, ambulatory surgery centers, and orthopedic surgeons for both pediatric and adult procedures, with implants engineered to degrade naturally in the body in approximately two years and eliminate the need for removal surgery.

Is Bioretec a public or private company?

Bioretec is a public company. It is classified as public and is currently operating.

When was Bioretec founded?

Bioretec was founded in 2003. It employs 51 to 100 people.

Where is Bioretec based?

Bioretec is headquartered in Tampere, Finland, in the Europe region.

How does Bioretec make money?

One revenue line is on record: orthopedic Implant Sales.

Who are Bioretec's main competitors?

Broad incumbents on record are Stryker, Johnson & Johnson (DePuy Synthes), Smith & Nephew and Zimmer Biomet. Direct peers are Arthrex, Integra LifeSciences, Orthofix Medical and CONMED. Emerging players are MedShape and Acuitive Technologies.

Does Bioretec have an API?

No public API is recorded for Bioretec.

What industry is Bioretec in?

Bioretec's product category is Orthopedic Implants / Bioabsorbable Medical Devices. Its primary akta.pro industry code is HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingBioretec clarifies stock option pricing differs for US taxpayersBioretec corrected its June 1 and July 7, 2026 stock option announcements, clarifying that the stated subscription price excludes some options. Options granted to US taxpayers use grant-date fair market value, with prices set separately and exceeding the standard subscription price by 20%. The maximum issuance remains unchanged at 182,970,807 options, with 12% dilution.The future of tradingBioretec Clarifies Stock Option Subscription Prices Vary for US TaxpayersBioretec corrected its June 1 and July 7, 2026 stock option announcements to clarify that subscription prices vary by jurisdiction. US grant prices are based on fair market value at each grant, and have so far equaled or exceeded the announced price. The maximum number of options remains unchanged at 182,970,807.news.cision.comCorrection: The Board of Directors of Bioretec Ltd resolved on a new stock option planBioretec's board resolved to establish a new stock option plan for about 30 key personnel and consultants. The plan grants up to 182,970,807 options, representing 12% of shares, with a subscription price of VWAP plus 20% premium, except for US grants priced at fair market value.MarketScreenerUS FDA Allows Bioretec to Commercialize Bioabsorbable Compression ScrewBioretec Oy, a Finland-based medical device manufacturer, is allowed to commercialize a bioabsorbable compression screw. The company's Activa product portfolio includes bioabsorbable biopolymer products for orthopedic applications, and it operates a Germany-based subsidiary.news.cision.comBioretec receives FDA 510(k) clearance for its ActivaScrew™ Cannulated COM bioabsorbable compression screwBioretec received FDA 510(k) clearance for its ActivaScrew Cannulated COM bioabsorbable compression screw, enabling U.S. commercialization. The clearance covers fixation of fractures, osteotomies, arthrodeses, and bone grafts in the upper and lower extremities for skeletally mature adults. The headless design aligns with surgeon preferences, supporting broader market reach.KauppalehtiBioretecin liikevaihto kasvoi reippaasti – Liiketappio odotettua suurempiBioretec reported a Q2 2024 net loss of €2.3 million, which was larger than the analyst-expected €1.7 million, despite revenue growing 62.2% to €1.1 million. The company's adjusted gross margin improved to 68.0%, and CEO Sarah van Hellenberg Hubar-Fisher highlighted strong growth in the US and Europe markets.news.cision.comBioretec Ltd’s Half-year report 2026: H1 close signals momentumBioretec reported H1 2026 net sales of EUR 2.32 million, up 11.9% year-over-year, with an adjusted sales margin of 69.2%. EBITDA was EUR -3.625 million and the result was EUR -4.678 million. The company plans to publish its Q3 business review on November 12, 2026.news.cision.comPanu Mikkonen appointed as Chief Financial Officer of BioretecBioretec appointed Panu Mikkonen as Chief Financial Officer, effective 6 October 2026. He brings nearly 30 years of finance experience, most recently as CFO of BPW Kraatz Group. He will oversee financial operations and support the company's international growth.KauppalehtiEtsitkö kovaa tuottoa ja siedät riskejä? Kauppalehti kokosi 10 osakkeen riskisalkunKauppalehti compiled a 10-stock risk portfolio consisting of Helsinki Stock Exchange-listed companies whose total returns vary more strongly compared to other stocks. The portfolio includes companies of various sizes ranging from smaller firms like Bioretec to established names such as Nokia, with examples like Neste, Metso, and Kempower cited as suitable for investors comfortable with volatility.KauppalehtiBioretecin johtoryhmään uusi nimiBioretec, a Finnish medical technology company, has appointed Conan Cavanagh as its Research and Development Director and management team member, effective September 1. Cavanagh will report to CEO Sarah van Hellenberg Hubar-Fisher and be responsible for R&D strategy, product portfolio management, and product development execution. The appointment aims to strengthen the company's technological development, clinical evidence, regulatory readiness, and long-term international competitiveness.